Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vaxcyte, Inc. (PCVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.00-0.77 (-3.11%)
At close: 04:00PM EDT
24.00 0.00 (0.00%)
After hours: 05:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close24.77
Open24.36
Bid23.97 x 900
Ask24.01 x 900
Day's Range23.66 - 25.29
52 Week Range16.78 - 29.73
Volume1,013,157
Avg. Volume391,952
Market Cap1.424B
Beta (5Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PCVX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaxcyte, Inc.
    ITOS: What does Argus have to say about ITOS?ITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

    -- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection to Prevent Invasive Pneumococcal Disease -- SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vaxcyt

  • Simply Wall St.

    We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

    -- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study Expected in October or November 2022 -- -- First Participants Dosed in Separate VAX-24 Phase 2 Clinical Study in Adults 65 Years and Older, with Topline Data Expected in the First Half of 2023 -- -- Received FDA Fast Track Desig

Advertisement
Advertisement